Australia's most trusted
source of pharma news
Thursday, 17 April 2025
Posted 7 April 2025 AM
Ferring Pharmaceuticals is working on bringing its gene treatment for bladder cancer to Australia.
The company has submitted a licence application to the Office of the Gene Technology Regulator for the import, transport, storage, and disposal of nadofaragene firadenovec, marketed as Adstiladrin in the United States.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.